424 related articles for article (PubMed ID: 35131666)
1. Diagnostic and prognostic implications of tumor expression of the GATA-3 gene in nodal peripheral T-cell lymphoma (nPTCL): Retrospective data from a Latin American cohort.
de Pádua Covas Lage LA; Brito CV; Levy D; Culler HF; Freitas Couto SC; de Oliveira LBA; Nogueira Zerbini MC; Rocha V; Pereira J
Leuk Res; 2022 Mar; 114():106794. PubMed ID: 35131666
[TBL] [Abstract][Full Text] [Related]
2. Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience.
Deng XW; Zhang XM; Wang WH; Wang SL; Jin J; Fang H; Ren H; Liu YP; He XH; Dong M; Song YW; Li YX
Ann Hematol; 2016 Aug; 95(8):1271-80. PubMed ID: 27209536
[TBL] [Abstract][Full Text] [Related]
3. Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study.
Piccaluga PP; Fuligni F; De Leo A; Bertuzzi C; Rossi M; Bacci F; Sabattini E; Agostinelli C; Gazzola A; Laginestra MA; Mannu C; Sapienza MR; Hartmann S; Hansmann ML; Piva R; Iqbal J; Chan JC; Weisenburger D; Vose JM; Bellei M; Federico M; Inghirami G; Zinzani PL; Pileri SA
J Clin Oncol; 2013 Aug; 31(24):3019-25. PubMed ID: 23857971
[TBL] [Abstract][Full Text] [Related]
4. TET-2 mutations predict poor outcomes and are associated with unfavorable clinical-biological features in PTCL, not otherwise specified and angioimmunoblastic T-cell lymphoma in Brazilian patients.
de Pádua Covas Lage LA; Barreto GC; Culler HF; Cavalcante JB; de Oliveira Alves LB; Nardinelli L; Bendit I; Zerbini MCN; Rocha V; Pereira J
Cancer Biomark; 2022; 35(2):179-191. PubMed ID: 36093687
[TBL] [Abstract][Full Text] [Related]
5. ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified.
ten Berge RL; de Bruin PC; Oudejans JJ; Ossenkoppele GJ; van der Valk P; Meijer CJ
Histopathology; 2003 Nov; 43(5):462-9. PubMed ID: 14636272
[TBL] [Abstract][Full Text] [Related]
6. The clinical features, treatment, and prognostic factors for peripheral T-cell lymphomas: A single-institution analysis of 240 Chinese patients.
Chen H; Tao Y; Zhou Y; Liu P; Yang J; He X; Zhou S; Qin Y; Song Y; Gui L; Zhang C; Yang S; Shi Y
Asia Pac J Clin Oncol; 2023 Oct; 19(5):e202-e214. PubMed ID: 35821612
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylated STAT3 as a potential diagnostic and predictive biomarker in ALK
Xiang C; Wu W; Fan M; Wang Z; Feng X; Liu C; Liu J; Liu G; Xia L; Si H; Gu Y; Liu N; Luo D; Wang Y; Ma D; Hu S; Liu H
Front Immunol; 2023; 14():1132834. PubMed ID: 37388733
[TBL] [Abstract][Full Text] [Related]
8. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.
Savage KJ; Harris NL; Vose JM; Ullrich F; Jaffe ES; Connors JM; Rimsza L; Pileri SA; Chhanabhai M; Gascoyne RD; Armitage JO; Weisenburger DD;
Blood; 2008 Jun; 111(12):5496-504. PubMed ID: 18385450
[TBL] [Abstract][Full Text] [Related]
9. Anaplastic large cell lymphoma, ALK-negative.
Ferreri AJ; Govi S; Pileri SA; Savage KJ
Crit Rev Oncol Hematol; 2013 Feb; 85(2):206-15. PubMed ID: 22789917
[TBL] [Abstract][Full Text] [Related]
10. [Expressions and clinical significance of GAS1, IL-1RAP and PRF1 in patients with ALK positive anaplastic large cell lymphoma].
Jiang Y; Cao D; Xu CG
Zhonghua Xue Ye Xue Za Zhi; 2018 Feb; 39(2):116-121. PubMed ID: 29562445
[No Abstract] [Full Text] [Related]
11. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.
Mak V; Hamm J; Chhanabhai M; Shenkier T; Klasa R; Sehn LH; Villa D; Gascoyne RD; Connors JM; Savage KJ
J Clin Oncol; 2013 Jun; 31(16):1970-6. PubMed ID: 23610113
[TBL] [Abstract][Full Text] [Related]
12. Proliferative, pro-inflammatory, and angiogenesis regulator gene expression profile defines prognosis in different histopathological subtypes of nodal peripheral T-cell lymphoma.
de Pádua Covas Lage LA; Levy D; Xavier FD; Reis DC; de Oliveira Costa R; Gonçalves MC; Rocha V; Zerbini MCN; Pereira J
Oncotarget; 2019 Aug; 10(50):5136-5151. PubMed ID: 31497245
[TBL] [Abstract][Full Text] [Related]
13. Serum IgA level, monocyte count, and international prognostic index are independently associated with overall survival in patients with HTLV-I-negative nodal peripheral T cell lymphoma.
Kato A; Imai Y; Aoki K; Tabata S; Matsushita A; Hashimoto H; Takahashi T; Ishikawa T
Ann Hematol; 2014 Jul; 93(7):1185-91. PubMed ID: 24526138
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological implications of immunohistochemical expression of TBX21, CXCR3, GATA3, CCR4, and TCF1 in nodal follicular helper T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified.
Han B; Lim S; Yim J; Song YK; Koh J; Kim S; Lee C; Kim YA; Jeon YK
J Pathol Transl Med; 2024 Mar; 58(2):59-71. PubMed ID: 38247153
[TBL] [Abstract][Full Text] [Related]
15. Outcome of combined modality treatment in first-line for stage I(E) peripheral T-cell lymphoma; a nationwide population-based cohort study from the Netherlands.
Meeuwes FO; Brink M; Plattel W; Van der Poel MWM; Kersten MJ; Wondergem M; Böhmer L; Woei-A-Jin FJSH; Visser O; Oostvogels R; Jansen PM; Neelis KJ; Crijns APG; Daniëls LA; Snijders TJF; Vermaat JSP; Huls GA; Nijland M
Haematologica; 2024 Apr; 109(4):1163-1170. PubMed ID: 37794805
[TBL] [Abstract][Full Text] [Related]
16. Clinical value of ALK and CD30 expression in mature systemic T cell lymphomas: analysis from the Czech Lymphoma Study Group database (NIHIL).
Janikova A; Michalka J; Chloupkova R; Kopalova N; Campr V; Kamaradova K; Kren L; Belada D; Benesova K; Dlouha J; Klener P; Procházka V; Mocikova H; Duras J; Trneny M
Ann Hematol; 2022 Apr; 101(4):789-798. PubMed ID: 35061088
[TBL] [Abstract][Full Text] [Related]
17. The clinical significance of activated p-AKT expression in peripheral T-cell lymphoma.
Hong JY; Hong ME; Choi MK; Chang W; Do IG; Jo JS; Jung SH; Park S; Kim SJ; Ko YH; Kim WS
Anticancer Res; 2015 Apr; 35(4):2465-74. PubMed ID: 25862915
[TBL] [Abstract][Full Text] [Related]
18. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.
Abramson JS; Feldman T; Kroll-Desrosiers AR; Muffly LS; Winer E; Flowers CR; Lansigan F; Nabhan C; Nastoupil LJ; Nath R; Goy A; Castillo JJ; Jagadeesh D; Woda B; Rosen ST; Smith SM; Evens AM
Ann Oncol; 2014 Nov; 25(11):2211-2217. PubMed ID: 25193992
[TBL] [Abstract][Full Text] [Related]
19. Pathobiology and molecular profiling of peripheral T-cell lymphomas.
de Leval L; Gaulard P
Hematology Am Soc Hematol Educ Program; 2008; ():272-9. PubMed ID: 19074096
[TBL] [Abstract][Full Text] [Related]
20. Molecular genetics of peripheral T-cell lymphomas.
Piccaluga PP; Tabanelli V; Pileri SA
Int J Hematol; 2014 Mar; 99(3):219-26. PubMed ID: 24481943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
